Skip to main content

Table 3 Comparative results of mean difference in coagulation profile among individuals using different lipid-lowering drugs

From: Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study

  Adjusted mean differencea (95%CI) Adjusted mean difference a (95% CI) Adjusted mean difference a (95% CI)
Fibrinogen, mg/dL
 Fibrate/Niacin users Reference Reference
 Other statin users Reference 18.6 (− 11.0 to 48.4)
 Rosuvastatin users 1.5 (−12.1 to 15.3) 20.7 (− 6.2 to 47.6)
 All statin users 19.1(− 10.0 to 48.2)
Factor VIII, IU/dL
 Fibrate/Niacin users Reference Reference
 Other statin users Reference − 15.5 (− 31.5 to 0.5)
 Rosuvastatin users −2.6 (− 10.1 to 4.7) − 17.6 (− 33.8 to −1.3)
 All statin users − 15.8 (− 31.6 to 0.003)
Factor IX, IU/dL
 Fibrate/Niacin users Reference Reference
 Other statin users Reference − 11.0 (− 22.7 to 0.7)
 Rosuvastatin users −2.3 (− 7.9 to 3.1) − 14.9 (− 29.7 to − 0.08)
 All statin users −11.3 (− 23.2 to 0.4)
Factor XI, IU/dL
 Fibrate/Niacin users Reference Reference
 Other statin users Reference −18.3 (− 27.4 to − 9.2)
 Rosuvastatin users 0.3 (−3.8 to 4.5) −17.6 (− 27.4 to − 7.7)
 All statin users − 18.3 (− 27.3 to − 9.4)
  1. CI confidence interval
  2. aadjusted for age, sex, body mass index, hypertension, smoking, diabetes, cardiovascular diseases